Could some breast cancer patients skip extra treatment? new trial investigates
NCT ID NCT07407920
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether patients with early HER2-positive or triple-negative breast cancer who had a complete response to pre-surgery treatment and have no cancer DNA in their blood can safely receive less therapy after surgery. The goal is to reduce side effects while keeping the cancer from coming back. The study involves 120 participants and uses drugs like pembrolizumab, trastuzumab, and pertuzumab.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab, trastuzumab, pertuzumab, endocrine therapy
What this could lead to
If successful, this could show that some patients with early breast cancer can safely receive less treatment after surgery, reducing side effects while maintaining good outcomes.
What could go wrong
This is a small, early-phase trial (120 participants) and may not prove that reduced therapy is as effective as standard care. There is a risk that cancer could return without full treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact